| 1 |
NCT01887639 |
Completed |
Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial |
- Non-psychotic Unipolar Major Depression
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of patients with unipolar major depression that do not achieve remission after one antidepressant treatment.
- Clinical, therapeutic and socio-demographic characteristics of resistant depression patients and comparisson of them with the characteristics of the sample of depressed patients in remission.
- Comparison of the depression severity change assessed by the physician with the evaluation done by the patient
|
200 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01887639 |
NIS-NAR-XXX-2013/1 |
PANTHER |
September 2013 |
September 2014 |
September 2014 |
June 27, 2013 |
July 30, 2015 |
|
- Research Site
Buenos Aires, Argentina - Research Site
Caba, Argentina - Research Site
Chaco, Argentina - (and 5 more...)
|
| 2 |
NCT01426997 |
Completed |
Phenotype Depression Study |
- Major Depressive Disorder
|
|
Observational |
|
- Emory University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- We are using clinician administered and self report psychiatric measurements to compare relevant symptom domains in patients with major depression and increased inflammation versus patients with major depression without increased inflammation.
- We are measuring immune markers for the identification of relevant immunologic patterns of activation in patients with major depression and increased inflammation versus patients with major depression without increased inflammation.
|
279 |
All |
21 Years to 65 Years (Adult) |
NCT01426997 |
IRB00039107
1R01MH087604-01A1 |
|
July 2010 |
May 2016 |
May 2016 |
September 1, 2011 |
June 22, 2016 |
|
- Emory University Department of Psychiatry and Behavioral Sciences
Atlanta, Georgia, United States
|
| 3 |
NCT02890212 |
Recruiting |
Selenium as Augmentation Treatment for Sertraline Resistant Major Depression |
|
- Dietary Supplement: selenium supplementation
- Dietary Supplement: placebo
|
Interventional |
Not Applicable |
- University of Sao Paulo General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depressive Rating Scale
- Montgomery-Asberg Depression Rating Scale
- Clinical Global Impression Scale
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT02890212 |
Selen-2015 |
|
August 2005 |
December 2017 |
December 2017 |
September 7, 2016 |
May 3, 2017 |
|
- Instituto de Psiquiatria - Hcfmusp
São Paulo, Brazil
|
| 4 |
NCT00825799 |
Completed |
Serum Markers as a Bioassay for Unipolar Depression |
|
|
Observational |
|
- Steward St. Elizabeth's Medical Center of Boston, Inc.
- Ridge Diagnostics Inc.
|
Other / Industry |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Protein biomarker MDDScore.
- Score on Hamilton Depression Rating Scale (HDRS).
|
160 |
All |
18 Years to 60 Years (Adult) |
NCT00825799 |
00435 |
|
November 2007 |
May 2011 |
May 2011 |
January 21, 2009 |
January 3, 2014 |
|
- Steward St. Elizabeth's Medical Center
Boston, Massachusetts, United States
|
| 5 |
NCT00122031 |
Completed |
Deep Brain Stimulation for Treatment-Refractory Major Depression |
|
- Device: Deep Brain Stimulation with Medtronic Activa Neurostimulator
|
Interventional |
Phase 1 |
- University Hospital, Bonn
- Medtronic
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale (HDRS)
- Montgomery-Asberg Depression Rating Scale (MADRS)
|
13 |
All |
20 Years to 65 Years (Adult) |
NCT00122031 |
BSG-04-006 |
|
July 2005 |
April 2009 |
January 2011 |
July 21, 2005 |
June 14, 2012 |
|
- Department of Psychiatry and Psychotherapy, University of Bonn
Bonn, Germany
|
| 6 |
NCT01151982 |
Completed |
Primary Prevention of Major Depression Based on the Level and Profile of Risk of Primary Care Attenders: Cluster, Controlled, Randomised Trial |
|
- Behavioral: Psychosocial Intervention
|
Interventional |
Not Applicable |
- The Mediterranean Institute for the Advance of Biotechnology and Health Research
- Preventive Services and Health Promotion Research Network
- Carlos III Health Institute
- Andaluz Health Service
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Prevention
|
- Accumulated incidence of major depression
- Cost-effectiveness and cost-utility
|
3326 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01151982 |
PS09/00081 |
predictD-CCRT |
October 2010 |
July 2012 |
January 2013 |
June 29, 2010 |
November 19, 2014 |
|
- Servicio Andaluz de Salud. Distrito Sanitario Málaga
Málaga, Spain - Málaga, Spain
|
| 7 |
NCT01391221 |
Unknown † |
Inflammatory Markers and Cognitive Function in Major Depression |
|
|
Interventional |
Phase 4 |
- Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine
- Eli Lilly and Company
- Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Cognitive function measured by CANTAB
- pain inhibition
- Allostatic load
|
20 |
All |
20 Years to 50 Years (Adult) |
NCT01391221 |
2011005 |
|
July 2011 |
August 2013 |
August 2013 |
July 11, 2011 |
July 19, 2012 |
|
- Centre de Recherche Fernand Seguin
Montreal, Quebec, Canada - Hôpital Maisonneuve Rosemont
Montreal, Quebec, Canada
|
| 8 |
NCT01685294 |
Completed |
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression |
- Major Depressive Disorder
|
- Behavioral: Group IPT for Depression + TAU
|
Interventional |
Phase 3 |
- Brown University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from Baseline in Hamilton Rating Scale for Depression (HRSD) at 3 Months
- Change from Baseline in Suicidality at 3 Months
- Change from Baseline in In-Prison Functioning at 3 Months
- (and 4 more...)
|
181 |
All |
18 Years and older (Adult, Senior) |
NCT01685294 |
1R01MH095230-01
R01MH095230 |
|
December 2011 |
October 2014 |
October 2014 |
September 14, 2012 |
January 13, 2016 |
|
- Massachusetts Correctional Institute - Old Colony Correctional Center
Bridgewater, Massachusetts, United States - Massachusetts Correctional Institution - Framingham
Framingham, Massachusetts, United States - South Middlesex Correctional Center
Framingham, Massachusetts, United States - (and 2 more...)
|
| 9 |
NCT00472576 |
Completed
Has Results |
Antidepressant Effects of NR2B in Major Depression |
|
- Drug: MK-0657
- Drug: Placebo
|
Interventional |
Phase 1 |
- National Institute of Mental Health (NIMH)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MADRS)
- Hamilton Depression Rating Scale (HDRS)
|
5 |
All |
18 Years to 55 Years (Adult) |
NCT00472576 |
070152
07-M-0152 |
|
May 2007 |
August 2009 |
August 2009 |
May 11, 2007 |
August 3, 2012 |
April 7, 2011 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 10 |
NCT01916824 |
Completed
Has Results |
Effects of Treatment on Decision-making in Major Depression |
- Major Depressive Disorder
- Healthy Controls
|
- Drug: Any FDA Approved Antidepressant
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
|
53 |
All |
18 Years to 65 Years (Adult) |
NCT01916824 |
IRB00066705 |
|
August 2013 |
December 2015 |
December 2015 |
August 6, 2013 |
November 21, 2017 |
October 20, 2017 |
- Emory Mood and Anxiety Disorders Program
Atlanta, Georgia, United States
|
| 11 |
NCT03060967 |
Not yet recruiting |
Assessment of Hedonic and Motivational States in Major Depression ( MOODDIS) |
|
- Behavioral: Computer-based tasks
|
Interventional |
Not Applicable |
- Institut National de la Santé Et de la Recherche Médicale, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Screening
|
- Point of subjective equality (PSE)
- Percentage of subjective discrimination (PSD)
|
72 |
All |
18 Years to 60 Years (Adult) |
NCT03060967 |
C15-88 |
MOODDIS |
June 2017 |
September 2020 |
September 2020 |
February 23, 2017 |
May 12, 2017 |
|
|
| 12 |
NCT01768052 |
Unknown † |
Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression |
|
- Device: functional Near Infrared Spectroscopy
|
Observational |
|
- Mclean Hospital
- National Alliance for Research on Schizophrenia and Depression
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Change in the connectivity strength in the CCN as assessed by fMRI
- Change in brain activation in DLPFC as assessed by fNIRS monitoring
|
40 |
All |
21 Years to 45 Years (Adult) |
NCT01768052 |
2012P002394 |
|
June 2013 |
January 2016 |
January 2016 |
January 15, 2013 |
May 4, 2015 |
|
- McLean Hospital
Belmont, Massachusetts, United States - McLean Imaging Center/McLean TMS Service
Belmont, Massachusetts, United States
|
| 13 |
NCT00675896 |
Completed |
A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome |
|
- Drug: Quetiapine Fumarate Sustained Release
- Drug: Placebo
|
Interventional |
Phase 4 |
- Dr Alexander McIntyre Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- last observation carried forward (LOCF) mean change from baseline to week 8 on the Hamilton Depression Scale (HAM-D) total score.
- Change from baseline to week 8 in: Brief Pain Inventory,HAM-A,CGI-S,FIQ, Sleep Scale from the Medical Outcome Study,SDS,QLES- Short Form,PHQ-15,Global Assessment Scale,Improvement (CGI-I) score from randomisation to Week 8
|
120 |
All |
18 Years to 65 Years (Adult) |
NCT00675896 |
D1443C00007 |
|
April 2007 |
June 2011 |
July 2011 |
May 12, 2008 |
July 6, 2011 |
|
- Dr. A McIntyre Inc
Penticton, British Columbia, Canada
|
| 14 |
NCT01360307 |
Completed |
Validation of the Spanish Version of the Clinically Useful Depression Outcome Scale (CUDOS) Scale |
|
|
Observational |
|
|
Industry |
- Time Perspective: Cross-Sectional
|
- Clinically Useful Depression Outcome Scale
- Hamilton Depression Rating Scale
- SF 36
- (and 3 more...)
|
330 |
All |
18 Years and older (Adult, Senior) |
NCT01360307 |
NIS-NES-XXX-2011/1 |
CUDOS |
June 2011 |
November 2011 |
November 2011 |
May 25, 2011 |
December 6, 2011 |
|
- Research Site
A Coruña, Spain - Research Site
Barcelona, Spain - Research Site
Cadiz, Spain - (and 14 more...)
|
| 15 |
NCT00149071 |
Completed |
Transcranial Magnetic Stimulation (rTMS) Accelerates the Response to Escitalopram in Major Depression |
|
|
Interventional |
Not Applicable |
- Hillerod Hospital, Denmark
- Medicon Valley Academy
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
|
61 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00149071 |
1,2 |
|
March 2004 |
|
January 2006 |
September 8, 2005 |
November 5, 2007 |
|
- Psychiatric research unit, Hilleroed Hospital,
Hillerod, Denmark
|
| 16 |
NCT00361374 |
Completed
Has Results |
Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression |
- Major Depressive Disorder
|
- Dietary Supplement: eicosapentaenoic acid
- Dietary Supplement: docosahexaenoic acid
- Drug: Placebo
|
Interventional |
Phase 3 |
- Massachusetts General Hospital
- Cedars-Sinai Medical Center
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Score on a Depression Severity Rating Scale Over Eight Weeks
|
196 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT00361374 |
2005P002337
5R01MH074085 |
|
July 2006 |
February 2013 |
March 2013 |
August 8, 2006 |
July 18, 2014 |
July 18, 2014 |
- Depression Clinical Research Program, Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 17 |
NCT01733654 |
Withdrawn |
Investigate Efficacy & Safety of RO4995819 vs. Placebo as Adjunct Tx in Patients w/Major Depressive Disorder |
- Depression
- Major Depressive Disorder
|
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery Asberg Depression Rating Scale
|
0 |
All |
18 Years to 65 Years (Adult) |
NCT01733654 |
23708 |
|
September 2012 |
December 2013 |
May 2014 |
November 27, 2012 |
September 12, 2013 |
|
|
| 18 |
NCT01579942 |
Terminated |
Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression |
- Major Depressive Disorder
|
|
Observational |
|
- Massachusetts General Hospital
- ElMindA Ltd
|
Other / Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Brain Network Analysis group patterns
- Identify possible predictors of treatment response
|
70 |
All |
18 Years to 55 Years (Adult) |
NCT01579942 |
2011P000200 |
|
April 2012 |
|
|
April 18, 2012 |
March 6, 2017 |
|
- Depression Clinical and Research Program
Boston, Massachusetts, United States
|
| 19 |
NCT00517036 |
Completed |
Omega-3 Fatty Acids for Treating Adults With Major Depression |
|
- Dietary Supplement: EPA omega-3 fatty acid
- Dietary Supplement: DHA omega-3 fatty acid
- Dietary Supplement: Placebo comparator
|
Interventional |
Phase 3 |
- Cedars-Sinai Medical Center
- National Institute of Mental Health (NIMH)
- Massachusetts General Hospital
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Depression rating scale score on HAM-D 17, SCID Mood Module
|
196 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT00517036 |
R01MH073765
DATR A5-ETMA |
|
July 2006 |
January 2011 |
January 2011 |
August 16, 2007 |
April 4, 2013 |
|
- Cedars-Sinai Medical Center
Los Angeles, California, United States
|
| 20 |
NCT00286546 |
Completed |
Testosterone and Major Depression |
|
|
Observational |
|
- University Health Network, Toronto
|
Other |
- Observational Model: Defined Population
- Observational Model: Natural History
- Time Perspective: Cross-Sectional
- Time Perspective: Prospective
|
|
100 |
Male |
40 Years to 65 Years (Adult) |
NCT00286546 |
002 |
|
January 2001 |
|
August 2005 |
February 3, 2006 |
September 11, 2006 |
|
- Toronto Western Hospital
Toronto, Ontario, Canada
|
| 21 |
NCT00159146 |
Terminated |
Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression |
|
- Drug: Pindolol and venlafaxin
|
Interventional |
Not Applicable |
- Hillerod Hospital, Denmark
- Wyeth is now a wholly owned subsidiary of Pfizer
- Tvergaards Foundation
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale scores
- Preskorn scores
|
31 |
All |
18 Years and older (Adult, Senior) |
NCT00159146 |
version 5 |
|
August 2002 |
|
September 2007 |
September 12, 2005 |
December 27, 2007 |
|
- Psychiatric Research Unit, Hillerod Hospital
Hillerod, Denmark
|
| 22 |
NCT00208702 |
Completed |
Thyroid Medication and Antidepressants for Treating Major Depression |
|
- Drug: Triiodothyronine
- Other: Placebo
- Drug: Sertraline
|
Interventional |
Phase 4 |
- Emory University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
|
153 |
All |
18 Years to 60 Years (Adult) |
NCT00208702 |
0431-1996
R01MH056946
431-1996
DSIR AT-SO |
|
September 1996 |
July 2003 |
July 2003 |
September 21, 2005 |
November 17, 2015 |
|
- Emory University
Atlanta, Georgia, United States
|
| 23 |
NCT02209142 |
Active, not recruiting |
Blood Biomarkers in Major Depression |
- Major Depressive Disorder
|
- Other: blood prelevement
- Other: psychometric data collection
|
Interventional |
Not Applicable |
- Assistance Publique Hopitaux De Marseille
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- describe a transcriptional signature of the Major Depressive Episode.
- evaluate the role played by confounding factors as genetic polymorphisms,
|
275 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02209142 |
2010-19 |
|
February 2012 |
November 2015 |
October 2016 |
August 5, 2014 |
July 27, 2016 |
|
- Assistance Publique Hopitaux de Marseille
Marseille, France
|
| 24 |
NCT00220623 |
Unknown † |
Efficacy of 18-Months of Antidepressive Medication Plus CBT or Dynamic or Supportive Psychotherapy for Recurrent Major Depression |
|
- Drug: antidepressant medications, flexible drug choice
- Behavioral: CBT, Psychodynamic or Supportive Psychotherapy
|
Interventional |
Phase 3 |
- Sir Mortimer B. Davis - Jewish General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single
- Primary Purpose: Treatment
|
- Time to recovery of major depressive episode
- Time to recurrence of major depression, once recovered
- improvement in depressive defenses
- (and 3 more...)
|
30 |
All |
18 Years to 65 Years (Adult) |
NCT00220623 |
#04-013 |
|
August 2004 |
|
|
September 22, 2005 |
September 22, 2005 |
|
- Institute of Community and Family Psychiatry
Montreal, Quebec, Canada
|
| 25 |
NCT00510822 |
Completed |
Cimicoxib for the Treatment of Major Depression (SECIM) |
|
- Drug: Cimicoxib
- Drug: Placebo
|
Interventional |
Phase 2 |
- Affectis Pharmaceuticals AG
- FGK Clinical Research GmbH
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- • Mean change on the total score of the Hamilton Depression Rating Scale (HamD-17) from baseline to endpoint (Week 6).
- • Changes from baseline to interim weekly visits (week 1 to 5) in HamD-17 score • Clinical Global Impression (CGI) score • Montgomery Asberg Depression Rating Scale (MADRS) score • Response rate, remission rate and drop out rate. • Onset of
|
169 |
All |
18 Years to 60 Years (Adult) |
NCT00510822 |
AFX-01
EudraCT-No. 2007-001335-54 |
|
October 2007 |
February 2010 |
February 2010 |
August 2, 2007 |
November 13, 2013 |
|
- Landeskrankenhaus Klagenfurt, Abteilung für Psychiatrie und Psychotherapie
Klagenfurt, Austria - Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft mbH
Salzburg, Austria - Faculty Hospital Brno
Brno, Czech Republic - (and 22 more...)
|
| 26 |
NCT03421847 |
Completed |
Study of Rotatory Vestibular Tests in Major Depression Patients and Healthy Control Subjects. |
- Depression
- Vestibular Disorder
|
- Diagnostic Test: Rotatory vestibular test
|
Observational |
|
- Vest Brain,Centro de Estudios Neurovestibulares
- Centro de Medicina Aeroespacial.
|
Other |
- Observational Model: Case-Control
- Time Perspective: Other
|
|
41 |
All |
18 Years and older (Adult, Senior) |
NCT03421847 |
ROTDEPR01 |
|
July 1, 2005 |
December 15, 2006 |
December 15, 2006 |
February 5, 2018 |
February 6, 2018 |
|
|
| 27 |
NCT00445237 |
Completed |
Evaluation of Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression |
|
- Device: H1 and H2 deep TMS coils
|
Interventional |
Phase 1 |
- Shalvata Mental Health Center
- Brainsway
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
|
All |
18 Years to 65 Years (Adult) |
NCT00445237 |
SH-505 |
|
May 2006 |
|
March 2008 |
March 8, 2007 |
February 5, 2009 |
|
- Shalvata MHC
Hod Hasharon, Israel
|
| 28 |
NCT00556140 |
Completed
Has Results |
The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression |
|
|
Interventional |
Phase 3 |
- Massachusetts General Hospital
- Bristol-Myers Squibb
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Depression and Psychosis Response Rate
- Depression and Psychosis Remission Rate
|
16 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT00556140 |
2003-P-000990 |
Abilify |
June 2003 |
January 2008 |
January 2008 |
November 9, 2007 |
August 20, 2012 |
August 20, 2012 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 29 |
NCT03347487 |
Recruiting |
Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression |
- Treatment Resistant Major Depression Disorder
|
- Procedure: Surgical Intervention
- Device: Shame DBS device followed by active DBS
- Device: Active DBS device followde by shame DBS
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- changes in the Hamilton Depression Scale(HAMD-17)
- changes in the Montgomery-Asberg Depression Rating Scale
- changes in the brain activity
- (and 4 more...)
|
6 |
All |
18 Years to 65 Years (Adult) |
NCT03347487 |
Habenula |
|
November 13, 2017 |
November 30, 2018 |
November 30, 2018 |
November 20, 2017 |
March 2, 2018 |
|
- Shanghai Ruijin Hospital Functional Neurosurgery
Shanghai, Shanghai, China
|
| 30 |
NCT00613912 |
Completed |
Advanced MRI in Major Depression |
- Depressive Disorder, Major
|
- Other: Magnetic Resonance Imaging
|
Observational |
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Differences in morphological and functional cerebral MRI findings in patients suffering from major depression
|
49 |
All |
20 Years to 65 Years (Adult) |
NCT00613912 |
AUFF-2005-740-004 |
|
March 2008 |
December 2009 |
June 2011 |
February 13, 2008 |
November 21, 2011 |
|
- Aalborg Hospital / Aarhus University Hospital
Aalborg, Jutland, Denmark
|
| 31 |
NCT00229645 |
Completed |
A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI's, and SNRI's Treatment in Major Depression With Anxiety |
- Major Depression With Comorbid Anxiety Symptoms
|
- Drug: Quetiapine Fumarate (Seroquel®)
|
Interventional |
Phase 4 |
- Dr Alexander McIntyre Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- To compare the efficacy of quetiapine versus placebo over 8 weeks as an adjunctive agent for unipolar non-psychotic adult outpatients on SSRI or SNRI therapy with residual symptoms of depression and comorbid anxiety symptoms. This will be measured by the
- 1. Hamilton Depression Scale (HAM-D) total score,
- 2. Hamilton Anxiety Scale (HAM-A) total score
|
60 |
All |
18 Years to 65 Years (Adult) |
NCT00229645 |
D1441C00017 |
|
November 2003 |
|
April 2005 |
September 30, 2005 |
July 13, 2016 |
|
- Dr. A. McIntyre
Penticton, British Columbia, Canada
|
| 32 |
NCT00285766 |
Completed |
Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression |
|
- Drug: Selegiline Transdermal System
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
300 |
All |
65 Years and older (Adult, Senior) |
NCT00285766 |
S9303-P0204 |
|
August 2002 |
|
July 2005 |
February 2, 2006 |
April 22, 2008 |
|
- Mohammed Bari, M.D.
Chula Vista, California, United States - Charles Meredith, M.D.
San Diego, California, United States - Daniel Zimbroff, M.D.
Upland, California, United States - (and 12 more...)
|
| 33 |
NCT03000530 |
Completed |
A Study to Evaluate SAGE-217 in Subjects With Moderate to Severe Major Depressive Disorder |
|
- Drug: SAGE-217
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety and tolerability, as assessed by adverse events [Part A]
- Safety and tolerability, as assessed by clinical laboratory measures [Part A]
- Safety and tolerability, as assessed by vital signs [Part A]
- (and 9 more...)
|
102 |
All |
18 Years to 65 Years (Adult) |
NCT03000530 |
217-MDD-201 |
|
December 2016 |
October 4, 2017 |
October 31, 2017 |
December 22, 2016 |
December 13, 2017 |
|
- Sage Investigational Site
Garden Grove, California, United States - Sage Investigational Site
Orlando, Florida, United States - Sage Investigational Site
Atlanta, Georgia, United States - (and 5 more...)
|
| 34 |
NCT01944657 |
Withdrawn |
Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study |
- 1. Major Depressive Disorder
|
- Device: Supplemental TMS
- Drug: Standard Medication Monotherapy
|
Interventional |
Not Applicable |
- Sheppard Pratt Health System
- Central Michigan University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Montgomery-Åsberg Depression Rating Scale (MADRS)
- Hamilton Rating Scale for Depression (HRSD)
|
0 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01944657 |
SPHS IRB [354612-3] |
|
September 2013 |
December 2015 |
December 2015 |
September 18, 2013 |
April 25, 2017 |
|
- Sheppard Pratt Health System
Towson, Maryland, United States
|
| 35 |
NCT00419003 |
Completed
Has Results |
Research Study for Major Depressive Disorder: Investigation of Glutamate Medications |
|
- Drug: Lamotrigine
- Drug: Ketamine
- Drug: Riluzole
|
Interventional |
Phase 4 |
- Baylor College of Medicine
- National Alliance for Research on Schizophrenia and Depression
- National Center for Research Resources (NCRR)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MARDS) Score (Acute Response to IV Ketamine in Patients With Treatment Resistant Major Depression)
- Efficacy of Lamotrigine in Decreasing IV Ketamine Psychotomimetic Side Effects
|
26 |
All |
21 Years to 70 Years (Adult, Senior) |
NCT00419003 |
05-0850
5M01RR000071-46 |
|
December 2006 |
July 2008 |
September 2008 |
January 5, 2007 |
March 21, 2016 |
March 21, 2016 |
- Mount Sinai School of Medicine
New York, New York, United States
|
| 36 |
NCT03230682 |
Recruiting |
Eealy Improvement Predicts Antidepressants Response in Adults With Major Depression Disorder |
- Major Depressive Disorder
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Early improvement
- Response
|
80 |
All |
16 Years to 55 Years (Child, Adult) |
NCT03230682 |
KY2017-01 |
|
July 25, 2017 |
June 11, 2018 |
July 11, 2018 |
July 26, 2017 |
July 26, 2017 |
|
- Dept. of Neurology, Huashan Hospital, Fudan University
Shanghai, Shanghai, China
|
| 37 |
NCT03228953 |
Recruiting |
Pharmacogenomic Testing in Major Depressive Disorder |
- Major Depressive Disorder
|
- Other: Pharmacogenomic testing
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- Score on the Hamilton Rating Scale for Depression (HAMD-17)
- Score on Subject-Rated 16-item Quick Inventory of Depression Symptomatology Scales (QIDS-SR)
- Score on the 9-item Patient Health Questionnaire (PHQ-9)
|
206 |
All |
21 Years to 80 Years (Adult, Senior) |
NCT03228953 |
AAAR4283 |
|
August 2017 |
May 15, 2021 |
May 15, 2021 |
July 25, 2017 |
August 4, 2017 |
|
- Columbia University Medical Center
New York, New York, United States
|
| 38 |
NCT02245373 |
Unknown † |
Cost-effectiveness of a Non-Pharmacological Treatment (Active Monitoring) vs. a Pharmacological Treatment for Major Depression in Primary Care. |
- Mild to Moderate Depression.
|
- Drug: Antidepressants
- Other: Active Monitoring
|
Observational |
|
- Fundació Sant Joan de Déu
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Compare the cost-effectiveness of active monitoring (standard treatment without antidepressants) vs antidepressants in mild major depression taking into account the severity and disability in Primary Care. The changes at Time Frame will be assessed.
- 1.Quality of life of patients with major depression who initiate treatment in Primary Care.
- 2. Cost-utility of an antidepressant vs no treatment in mild Depression in Primary.
|
263 |
All |
18 Years and older (Adult, Senior) |
NCT02245373 |
Infap |
|
June 2013 |
July 2014 |
July 2015 |
September 19, 2014 |
September 19, 2014 |
|
|
| 39 |
NCT00770783 |
Unknown † |
Magnetic Seizure Therapy (MST) for Treatment Resistant Major Depression |
|
- Device: Thymatron
- Device: Tonica MagPro MST
|
Interventional |
Phase 3 |
- University Hospital, Bonn
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Clinical improvement (Hamilton Rating Scale for Depression)
- Clinical improvement (Montgomery- Åsberg Rating Scale for Depression)
|
30 |
All |
18 Years to 65 Years (Adult) |
NCT00770783 |
BSG-05-001 |
|
February 2005 |
September 2013 |
May 2014 |
October 10, 2008 |
October 29, 2013 |
|
- Department of Psychiatry and Psychotherapy - University Hospital
Bonn, Germany
|
| 40 |
NCT01027559 |
Completed |
fMRI Study of Treatment Changes in Major Depression |
- Major Depression
- Treatment
|
- Drug: Sertraline
- Behavioral: Cognitive Behavioral Therapy
|
Interventional |
Not Applicable |
- Washington University School of Medicine
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
|
- Activation differences between pre- and post-treatment fMRI scans.
- A 50% or greater drop in Hamilton Depression Rating Scale signifies response to treatment.
|
97 |
All |
18 Years to 50 Years (Adult) |
NCT01027559 |
081348
R01MH064821
2R01MH064821-05A2
DDTR A3-NSI |
|
February 2009 |
January 2014 |
January 2014 |
December 8, 2009 |
December 19, 2014 |
|
- Washington University
St. Louis, Missouri, United States
|
| 41 |
NCT00461279 |
Completed |
Attachment Security as Mediator and Moderator of Outcome in Major Depression |
|
- Behavioral: Cognitive Behavior Therapy
- Behavioral: Interpersonal Psychotherapy
|
Interventional |
Not Applicable |
- Centre for Addiction and Mental Health
- Ontario Mental Health Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
134 |
All |
18 Years and older (Adult, Senior) |
NCT00461279 |
165/2006 |
|
August 2006 |
February 2010 |
March 2010 |
April 17, 2007 |
December 6, 2011 |
|
- Centre for Addiction and Mental Health
Toronto, Ontario, Canada
|
| 42 |
NCT01182103 |
Completed
Has Results |
Epigenetic Regulation of BDNF in Major Depression |
- Major Depressive Disorder
|
|
Observational |
|
- Chang Gung Memorial Hospital
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Brain-derived Neurotrophic Factor (BDNF) DNA Methylation of Major Depressive Disorder (MDD) Patients and Healthy Controls
- Histone Modification of MDD Patients Before and After Treatment and With Healthy Controls
- BDNF Levels of MDD Patients Before and After Treatment and Healthy Controls
|
110 |
All |
18 Years to 60 Years (Adult) |
NCT01182103 |
NSC99-2628-B-182-002-MY2 |
|
August 2010 |
July 2012 |
May 2013 |
August 16, 2010 |
August 15, 2014 |
August 15, 2014 |
- Department of Psychiatry, Chang Gung Memorial Hospital
Kaohsiung, Taiwan
|
| 43 |
NCT00611052 |
Terminated |
Prevention of Adolescent Major Depression |
|
- Behavioral: the Adolescent Coping with Stress
- Behavioral: Treatment as usual
- Other: usual health education
|
Interventional |
Not Applicable |
- National Institute for Health and Welfare, Finland
- Helsinki University
- University of Eastern Finland
- (and 4 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Prevention
|
- Major depression (diagnostic interview) High level of depressive symptoms (self-report scale)
- Suicidality (diagnostic interview, self-report scale)
|
65 |
All |
14 Years to 16 Years (Child) |
NCT00611052 |
KTL423-0 |
CWSA-Fin |
March 2008 |
December 2013 |
December 2013 |
February 8, 2008 |
April 20, 2016 |
|
- Kuopio University Hospital and Kuopio University
Kuopio, Finland - Turku Primary Health care and Adolescent Psychiatric clinic
Turku, Finland - Vantaa Primary Health Care
Vantaa, Finland
|
| 44 |
NCT03254017 |
Recruiting |
Remotely Programmed Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression: An Open Label Pilot Trial |
- Treatment Resistant Major Depressive Disorder
|
- Procedure: Bilateral surgical implantation of DBS system to Habeluna
- Other: Follow-up Period
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the Montgomery-Asberg Depression Rating Scale
- Change in the Hamilton Depression Scale
- Change in the Hamilton Anxiety Scale
- (and 5 more...)
|
6 |
All |
18 Years to 65 Years (Adult) |
NCT03254017 |
Habenula DBS |
|
July 24, 2017 |
July 30, 2018 |
August 30, 2019 |
August 18, 2017 |
March 2, 2018 |
|
- Shanghai Ruijin Hospital Functional Neurosurgery
Shanghai, Shanghai, China - Shanghai Ruijin Hospital Functional Neurosurgery
Shanghai, Shanghai, China
|
| 45 |
NCT00168272 |
Completed |
Priming rTMS In Major Depression |
- Major Depressive Disorder
|
- Device: Transcranial Magnetic Stimulation
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- The primary outcome measure used is the MADRS (Montgomery-Asberg Depression Rating Scale). At study end response criteria is defined as a 50% reduction in total MADRS score and remission defined as less or equal to 10.
- Other outcome measures administered fortnightly are: BPRS (Brief Psychiatric Rating Scale), CORE (measure of melancholic symptoms), BDI (Beck Depression Inventory), CGI (Clinical Global Impression Scale), GAF (Global Assessment of Functioning Scale).
|
100 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00168272 |
5/04 |
|
June 2004 |
|
March 2007 |
September 15, 2005 |
April 16, 2007 |
|
- Alfred Psychiatry Research Centre
Melbourne, Victoria, Australia
|
| 46 |
NCT02165449 |
Recruiting |
Biomarkers of Fast Acting Therapies in Major Depression |
- Major Depressive Disorder
|
|
Interventional |
Phase 1 |
- University of California, Los Angeles
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the Hamilton Depression Rating Scale measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions
- Change in the Hamilton Depression Rating Scale measured between the last ketamine infusion treatment and 5 week follow-up
- Change in gene expression measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions
- (and 7 more...)
|
60 |
All |
18 Years to 64 Years (Adult) |
NCT02165449 |
HS001796
K24MH102743
U01MH110008 |
|
June 2014 |
August 2020 |
August 2021 |
June 17, 2014 |
February 13, 2018 |
|
- Geffen School of Medicine, UCLA
Los Angeles, California, United States
|
| 47 |
NCT02139540 |
Unknown † |
Nitrous Oxide as Treatment for Major Depression - a Pilot Study |
- Depression
- Major Depressive Disorder
|
- Drug: Nitrous Oxide
- Drug: Placebo
|
Interventional |
Phase 2 |
- Washington University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in HDRS-21 (21-point Hamilton Depression Rating Scale)
- Change in QIDS -SR [Quick Inventory of Depressive Symptomatology - Self Report]
- Clinical Depression Endpoints
- Change in Plasma Total Homocysteine
|
40 |
All |
18 Years to 65 Years (Adult) |
NCT02139540 |
201204023 |
|
November 2012 |
December 2016 |
December 2016 |
May 15, 2014 |
January 14, 2016 |
|
- Barnes-Jewish Hospital
St. Louis, Missouri, United States
|
| 48 |
NCT00326677 |
Unknown † |
Primary Prevention of Major Depression in Later Life |
|
- Behavioral: Problem Solving Therapy
- Behavioral: Dietary Education
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- BDI, Hamilton, FDI scores, SCID diagnosis of major depression
- CES-D, ISEL,Folstein Mini-Mental, MOS-SF8,BSI, EXIT, Hopkins Verbal Learning Test, PTSD Checklist, Social Problem Solving Inventory, PSQI, CIRS-G, RAND 12
|
306 |
All |
50 Years and older (Adult, Senior) |
NCT00326677 |
0601117 |
|
May 2006 |
June 2012 |
December 2013 |
May 17, 2006 |
February 18, 2011 |
|
- University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States - University of Pittsburgh
Pittsburgh, Pennsylvania, United States
|
| 49 |
NCT01357083 |
Completed |
The Study of Serum Melatonin Rhythm Levels in Patients With Major Depressive Disorder |
- Major Depressive Disorder
|
|
Observational |
|
- Science & Research Islamic Azad University Branch Khozestan
|
Other |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
- Depression status(measured by Beck depression inventory (BDII-II))
- Measurements of morning and nocturnal melatonin levels by ELISA kit (cat no. RE54021) from the IBL-Hamburg.
|
92 |
All |
22 Years to 48 Years (Adult) |
NCT01357083 |
9460
CCT-NAPN-21087 |
|
August 2010 |
October 2010 |
October 2010 |
May 20, 2011 |
May 20, 2011 |
|
- Shahnaz Khaleghipour
Isfahan, Iran, Islamic Republic of
|
| 50 |
NCT01611818 |
Completed |
Low Intensity Versus Self-guided Internet-delivered Psychotherapy for Major Depression |
|
- Other: Low Intensity Internet-delivered psychotherapy
- Other: Self-guided Internet delivered psychotherapy
- Other: Improved treatment as usual
|
Interventional |
Not Applicable |
- Javier Garcia Campayo
- Carlos III Health Institute
- Hospital Miguel Servet
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Severity of depressive symptomatology measured by Beck Depression Inventory II
- Socio-demographic variables.
- Mini-International Neuropsychiatric Interview (MINI).
- (and 5 more...)
|
300 |
All |
18 Years to 65 Years (Adult) |
NCT01611818 |
PI10/01083 |
|
September 2012 |
December 2014 |
December 2016 |
June 5, 2012 |
August 10, 2017 |
|
- Hospital Parc Sanitari Sant Joan de Deu
Sant Boi de Llobregat, Barcelona, Spain - Health Science Research Institute, University Balearic Islands
Palma de Mallorca, Mallorca, Spain - Psychiatric Service. Hospital Vall D'Hebrón
Barcelona, Spain - (and 3 more...)
|
Create an RSS feed from your search for:
Download the search results for: